Welcome to our dedicated page for Coherus news (Ticker: CHRS), a resource for investors and traders seeking the latest updates and insights on Coherus stock.
Coherus Oncology, Inc. reports commercial-stage oncology developments centered on LOQTORZI® (toripalimab-tpzi), an approved next-generation PD-1 inhibitor for recurrent or metastatic nasopharyngeal carcinoma. Company updates also cover its antibody immunotherapy pipeline, including tagmokitug, an anti-CCR8 cytolytic antibody, and casdozokitug, an IL-27 antagonistic antibody, across solid-tumor programs such as liver, prostate, head and neck, colorectal, gastric and esophageal cancers.
Recurring news includes financial results, LOQTORZI revenue commentary, clinical-development updates, strategic partnerships, investor-conference presentations, public common-stock offerings, debt reduction and other capital-structure actions tied to the company's transition from biosimilars to innovative oncology.
Coherus Oncology (Nasdaq: CHRS) reported Q1 2026 net revenue from continuing operations of $12.3 million, with LOQTORZI net revenue of $11.8 million, up 61% year over year and down 5% sequentially. Net loss narrowed to $36.9 million from $47.4 million.
Cash, cash equivalents and marketable securities totaled $167.0 million at March 31, 2026. The company raised $53.6 million net via a public offering of 32.89 million shares. Key pipeline updates include full enrollment of the randomized Phase 2 casdozokitug uHCC trial and multiple ongoing Phase 1b tagmokitug combination studies with data readouts expected in 2026.
Coherus Oncology (Nasdaq: CHRS) will release first quarter 2026 financial results after market close on Monday, May 11, 2026.
The company will host a management conference call and webcast starting at 5:00 p.m. Eastern Time on May 11, 2026. A replay and press release will be available at https://investors.coherus.com.
Coherus Oncology (NASDAQ: CHRS) reported full-year and Q4 2025 results, highlighting commercial growth for LOQTORZI, major debt reduction, cash position and pipeline progress. LOQTORZI revenue more than doubled to $40.8M in 2025. Secured and convertible debt was reduced ~90% to $38.8M. Cash and marketable securities totaled $172.1M at year-end. The company reported a 2025 net loss of $183.1M and ongoing R&D investment in tagmokitug and casdozokitug with multiple clinical readouts expected in 2026.
Notable clinical data include a 6-year OS median of 64.8 months vs 33.7 months for chemotherapy in JUPITER-02 (HR 0.62), and a prior Phase 2 casdozokitug CR rate of 17%.
Coherus Oncology (Nasdaq: CHRS) will release its full year and fourth quarter 2025 financial results after market close on Monday, March 9, 2026. A management conference call and webcast will begin at 4:30 p.m. ET the same day, with a replay posted on the company investor website.
Investors can pre-register for dial-in details and PIN, and the press release and related materials will be available on the Coherus investor site before the call.
Coherus Oncology (NASDAQ: CHRS) said senior management will present at two investor conferences in March 2026 with webcasts and replays available on the company investor events calendar.
Presentations: TD Cowen Healthcare Conference on March 4, 2026 at 11:50 AM ET and Citizens Life Sciences Conference on March 10, 2026 at 2:50 PM ET. Replays will be posted for approximately 90 days.
Coherus Oncology (NASDAQ: CHRS) closed an underwritten public offering of 28,600,000 common shares at $1.75 per share on Feb 17, 2026, generating approximately $50.1 million gross proceeds before fees.
The company granted underwriters a 30-day option to purchase up to 4,290,000 additional shares for over-allotments. Proceeds will support commercialization of LOQTORZI, continued clinical programs, working capital and general corporate purposes.
Coherus Oncology (NASDAQ: CHRS) priced an underwritten public offering of 28,600,000 common shares at $1.75 per share, raising approximately $50.1 million in gross proceeds. The company granted a 30-day option for an additional 4,290,000 shares and expects closing on or about February 17, 2026.
Net proceeds are intended to support commercialization of LOQTORZI (toripalimab-tpzi), continue clinical development, and for working capital and general corporate purposes.
Coherus Oncology (NASDAQ: CHRS) announced a proposed underwritten public offering of its common stock on Feb 12, 2026.
Key points: Coherus will offer shares from its effective Form S-3 shelf (File No. 333-291520, filed Nov 13, 2025); underwriters have a 30-day option for up to 15% additional shares. Net proceeds are targeted to support commercialization of LOQTORZI (toripalimab-tpzi), continue clinical development, and for working capital and general corporate purposes. The Offering is subject to market conditions and may not be completed as proposed.
Coherus Oncology (NASDAQ: CHRS) said senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 10:30 a.m. PT.
The presentation and Q&A will stream via webcast and a link will be posted on the company's Investor Events Calendar at https://investors.coherus.com/events-presentations. The webcast replay will be available through February 13, 2026.
Coherus Oncology (NASDAQ: CHRS) announced publication in Molecular Cancer Therapeutics describing preclinical and first-in-human biomarker data for investigational anti-CCR8 antibody tagmokitug (CHS-114).
Key findings: picomolar binding affinity, no off-target binding, selective depletion of CCR8+ regulatory T cells, high prevalence and density of CCR8 across many solid tumors, tumor regression in mouse models with enhanced activity when combined with anti-PD-1, and translational proof-of-mechanism showing selective CCR8+ Treg reductions in patients.
The publication supports ongoing clinical development of tagmokitug in combination with toripalimab across multiple solid tumor settings.